abdala (vaccine) abdala (vaccine) abdala, technical name cigb-66, is a covid-19 vaccine developed by the center for genetic engineering and biotechnology in cuba. this candidate, named after a patriotic drama by cuban independence hero josé martí, is a protein subunit vaccine containing covid-derived proteins that trigger an immune response. the full results of the clinical trial have not yet been published. this candidate followed a previous one called cigb-669 (mambisa). abdalavaccine descriptiontargetsars-cov-2vaccine typeprotein subunitclinical dataother namesabdalaroutes ofadministrationintramuscularlegal statuslegal status full and emergency authorizations full list of abdala authorizations part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal the vaccine is one of two cuba-developed covid-19 vaccines which has passed phase iii trials, and has received emergency authorisation. medical uses the vaccine was administered in 3 doses spaced 2 weeks apart. efficacy on 22 june 2021, the official cuban government sources reported that the results of an initial study by the cuban center for genetic engineering and biotechnology involving 48,290 participants found a 92.28% efficacy rate at preventing symptomatic covid-19. the report included a confidence interval of 85.74%–95.817% without a specified confidence level; analysis was based on 153 cases of symptomatic covid, 142 of which were in the placebo group and 11 of which were in the approximately equal vaccinated group. the measure of efficacy includes the initial strain of sars-cov-2 as well as variants that were present in cuba during the study, including alpha, beta, and gamma strains. the beta variant entered cuba in january 2021 and became the predominant strain in cuba, fuelling a rise in covid cases. as of 28 june 2021, cuba has not yet released detailed information about the vaccine to the who or to the general public via a pre-print or a scientific article. it is planned to do so after the cuba health agency (cecmed) authorises the vaccine for emergency use. vaccine design the vaccine was designed by researchers from the center for genetic engineering and biotechnology and has been described in a pre-print submission. the abdala vaccine reportedly consists of a monomeric receptor binding domain subunit, residues 331-530 of the spike protein of sars-cov-2 strain 156 wuhan-hu-1, expressed in the yeast pichia pastoris at 30–40 mg/l fermentation yield. the vaccine antigen is polyhistidine-tagged to aid purification and is reportedly purified via immobilised metal affinity chromatography and subsequent hydrophobic interaction chromatography to >98% purity. for animal studies 50 µg of vaccine antigen per dose was adjuvanted with 0.3 mg aluminium hydroxide gel (alhydrogel) and delivered in 500 µl phosphate buffer. manufacturing venezuela has claimed that it will manufacture the vaccine but, as of 2 may 2021, this claim had not yet materialised. state-owned espromedbio will manufacture the vaccine but some "arrangements" are needed to start production. in april, nicolás maduro said that a capacity of 2 million doses per month is hoped to be reached by august or september 2021. in june 2021, vietnam's ministry of health announced that negotiations were ongoing between cuba and vietnam for abdala vaccine production. the institute of vaccines and medical biologicals (ivac) was named as the focal point for receiving technology transfer. history clinical trials in july 2020, abdala commenced phase i/ii clinical trials. the phase iii trial compares 3 doses of the vaccine administered at 0, 14 and 28 days against a placebo, with the primary outcome measuring the proportion of cases reported for each group 14 days after the third dose. the trial was registered on 18 march 2021. the first dose was administered on 22 march and by april 4, the 48,000 participants had received their first dose, and second doses started being administered from april 5. third doses have started being administered on 19 april and on may 1, adherence to the three-dose protocol was over 97%. in july 2021, abdala started clinical trial phase i/ii for children and adolescents aged 3-18. intervention study 124,000 people aged 19 to 80 received 3 doses of the vaccine as part of an intervention study, with the primary outcome measuring the proportion of cases and deaths for the vaccinated compared to the unvaccinated population. a wider intervention study with the 1.7 million inhabitants of havana is expected to start in may with the abdala and soberana 2 vaccine. authorizations full authorization emergency authorization allowed for travel